Latin America Liver Cancer Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 7.90 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Latin America Liver Cancer Treatment Market Analysis
The Latin American liver cancer treatment market is expected to register a CAGR of nearly 7.9% during the forecast period. Changes in the current lifestyle of individuals led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type-2 diabetes, metabolic disorders, excess body weight, alcohol consumption, and tobacco smoking. It has also been observed that liver cancer risk increases substantially with the increase in one's body mass index (BMI). According to the OECD Obesity Update 2017, obesity levels are particularly high in Latin American countries. For example, in Mexico, 32.4% of males aged 15 years and over are obese as of 2017, and nearly 39% of the population is projected to become obese by 2030. Thus, owing to the above factors, the market is expected to show growth in the near future.
Latin America Liver Cancer Treatment Market Trends
This section covers the major market trends shaping the Latin America Liver Cancer Treatment Market according to our research experts:
Hepatocellular Carcinoma Segment is Expected to Hold a Major Share in the Latin America Liver Cancer Treatment Market
Hepatocellular carcinoma is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver disease, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths, globally. It is observed that the developing countries of the Latin American region have higher incidence rates of hepatocellular carcinoma than the developed countries, due to the disparity in the major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, causing hepatocellular carcinoma in those regions. With the increase in the incidence of hepatocellular carcinoma, liver cancer therapeutics is expected to have huge demand. Hence, the rising incidence of cancer and high unmet medical needs are the major factors driving the market in the forecast period.
Latin America Liver Cancer Treatment Industry Overview
The Latin American liver cancer treatment market is consolidated, with some major players controlling the major share of the market, especially in the diagnostics space. Liver cancer diagnostics are majorly dependent on high-cost diagnostic imaging modalities, such as MRI, CT, and PET scanners. There are few major players in the global market, and due to the low volume of demand in Latin American countries, the concentration of medical device manufacturers is even lower. In the Latin American therapeutic space, several niche players operate, and various clinical trials are underway. Some of the companies that are currently dominating the market are Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Inc, Eisai Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Eli Lilly And Co., Onyx Pharmaceuticals Inc., and Pfizer Inc.
Latin America Liver Cancer Treatment Market Leaders
-
Bayer AG
-
Bristol-Myers Squibb Company
-
Merck & Co., Inc
-
Eisai Inc.
-
Exelixis, Inc
*Disclaimer: Major Players sorted in no particular order
Latin America Liver Cancer Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Burden of Liver Cancer
- 4.2.2 Technological Advancements in Treatments by Biopharmaceutical Companies
-
4.3 Market Restraints
- 4.3.1 Adverse Effects of Drugs
- 4.3.2 High Cost
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Type
- 5.1.1 Hepatocellular Carcinoma
- 5.1.2 Cholangio Carcinoma
- 5.1.3 Hepatoblastoma
- 5.1.4 Other Types
-
5.2 By Therapy
- 5.2.1 Targeted Therapy
- 5.2.2 Radiation Therapy
- 5.2.3 Immunotherapy
- 5.2.4 Chemotherapy
- 5.2.5 Other Therapies
-
5.3 Geography
- 5.3.1 Latin America
- 5.3.1.1 Mexico
- 5.3.1.2 Brazil
- 5.3.1.3 Argentina
- 5.3.1.4 Rest of Latin America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Alnylam Pharmaceuticals Inc.
- 6.1.2 Bayer AG
- 6.1.3 Bristol-Myers Squibb Company
- 6.1.4 Eli Lilly And Co.
- 6.1.5 Merck & Co. Inc.
- 6.1.6 Eisai Inc.
- 6.1.7 Onyx Pharmaceuticals Inc.
- 6.1.8 Pfizer Inc.
- 6.1.9 Exelixis Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Latin America Liver Cancer Treatment Industry Segmentation
As per the scope of the report, liver cancer is a cancer that begins in the cells of the liver. The most common type of liver cancer is hepatocellular carcinoma, which begins in the liver cell called (hepatocyte). Other types of liver cancer, such as intrahepatic cholangiocarcinoma and hepatoblastoma, are much less common. The Latin American liver cancer treatment market is segmented by type, therapy, and geography.
| By Type | Hepatocellular Carcinoma | |
| Cholangio Carcinoma | ||
| Hepatoblastoma | ||
| Other Types | ||
| By Therapy | Targeted Therapy | |
| Radiation Therapy | ||
| Immunotherapy | ||
| Chemotherapy | ||
| Other Therapies | ||
| Geography | Latin America | Mexico |
| Brazil | ||
| Argentina | ||
| Rest of Latin America |
Latin America Liver Cancer Treatment Market Research FAQs
What is the current Latin America Liver Cancer Treatment Market size?
The Latin America Liver Cancer Treatment Market is projected to register a CAGR of 7.90% during the forecast period (2024-2029)
Who are the key players in Latin America Liver Cancer Treatment Market?
Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Inc, Eisai Inc. and Exelixis, Inc are the major companies operating in the Latin America Liver Cancer Treatment Market.
What years does this Latin America Liver Cancer Treatment Market cover?
The report covers the Latin America Liver Cancer Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Latin America Liver Cancer Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Latin America Liver Cancer Treatment Industry Report
Statistics for the 2024 Latin America Liver Cancer Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Liver Cancer Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
